Similar Papers

Paper Title
Journal
Date
Author
Abstract LB_A17: Trial in progress: First-in-human phase I dose-escalation study of a novel Bicycle toxin conjugate (BT5528) targeting EphA2 in patients with advanced solid tumors
Elisa Fontana ... Hanna Orr
Molecular Cancer Therapeutics | VOL. 22
Elisa Fontana, et. al.Elisa Fontana ... Hanna Orr
01 Dec 2023
Breaking from the paradigm of antibody-drug conjugates: Evaluation of clinical pharmacokinetics and safety of bicycle toxin conjugates (BTCs).
Justin Bader ... Yasong Lu
Journal of Clinical Oncology | VOL. 42
Justin Bader, et. al.Justin Bader ... Yasong Lu
01 Jun 2024
464P - Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours
N Cook ... S.N Symeonides
Annals of Oncology | VOL. 30
N Cook, et. al.N Cook ... S.N Symeonides
01 Oct 2019
The validation and clinical bioanalysis of the Bicycle® Toxin Conjugate zelenectide pevedotin in human plasma.
Joseph A Tweed ... Hongmei Xu
Bioanalysis | VOL. -
Joseph A Tweed, et. al.Joseph A Tweed ... Hongmei Xu
19 Jan 2025
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial
Marcela Carausu ... Michail Ignatiadis
Annals of Oncology | VOL. 36
Marcela Carausu, et. al.Marcela Carausu ... Michail Ignatiadis
01 Feb 2025
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Feb 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Feb 2025
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.